Health Care & Life Sciences » Biotechnology | Emergent Biosolutions Inc.

Emergent Biosolutions Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
32,011.00
43,969.00
62,870.00
51,776.00
82,594.00
62,700
Depreciation, Depletion & Amortization
18,958.00
32,453.00
35,335.00
38,229.00
42,572.00
62,200
Other Funds
2,751.00
4,408.00
5,588.00
35,766.00
15,201.00
27,400
Funds from Operations
72,825.00
98,777.00
110,363.00
98,937.00
154,415.00
160,900
Changes in Working Capital
24,143.00
13,541.00
65,904.00
45,450.00
53,724.00
119,100
Net Operating Cash Flow
96,968.00
112,318.00
44,459.00
53,487.00
208,139.00
41,800
Capital Expenditures
42,021.00
30,673.00
44,812.00
76,257.00
54,828.00
Net Investing Cash Flow
67,894.00
210,052.00
45,462.00
76,257.00
249,932.00
Issuance/Reduction of Debt, Net
774.00
180,588.00
2,000.00
-
20,000.00
Net Financing Cash Flow
8,612.00
198,874.00
33,449.00
18,641.00
50,358.00
Net Change in Cash
37,672.00
101,161.00
32,296.00
41,282.00
92,178.00
Free Cash Flow
54,947.00
81,645.00
353.00
22,770.00
153,311.00
Deferred Taxes & Investment Tax Credit
13,858.00
16,493.00
3,464.00
5,190.00
3,259.00
8,600
Net Assets from Acquisitions
25,873.00
179,379.00
650.00
-
195,104.00
Change in Capital Stock
6,635.00
13,878.00
25,861.00
17,125.00
13,731.00
Exchange Rate Effect
14.00
21.00
150.00
129.00
27.00

About Emergent Biosolutions

View Profile
Address
400 Professional Drive
Gaithersburg Maryland 20879
United States
Employees -
Website http://www.emergentbiosolutions.com
Updated 07/08/2019
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.